Management of fetal－maternal hemorrhage of RhD isoimmunization during pregnancy

doi:10.3877/cma.j.issn.2095-3259.2015.01.010

Abstract

Abstract:

Fetal-maternal hemorrhage of RhD isoimmunization is maternal antibodies of Rh-negative pregnant woman affecting the RhD red cell antigen of Rh-positive fetus, which may result in hemolytic disease of the fetus/newborn, even stillbirth. Prior to the use of anti-D immune globulin, the incidence rate of the fetus/newborn hemolytic disease is high. Implement RhD immune globulin prophylaxis normatively and monitor fetal during pregnancy carefully can led to a significant reduction in the frequency of perinatal mortality and morbidity.

Key words: Rh isoimmunization, Blood group incompatibility, Rh(D) immune globulin, Hemolysis

Yan Yin, Qiying Zhu. Management of fetal－maternal hemorrhage of RhD isoimmunization during pregnancy[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2015, 04(01): 44-47.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhckjjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3259.2015.01.010

https://zhckjjdzzz.cma-cmc.com.cn/EN/Y2015/V04/I01/44

References 24

[1]	Bolton-Maggs PH, Davies T, Poles D, et al. Errors in anti-D immunoglobulin administration: retrospective analysis of 15 years of reports to the UK confidential haemovigilance scheme[J]．Int J Obstet Gynaecol, 2013，120(7):873-878.
[2]	Abdel-Fattah SA, Soothill PW, Carroll SG, et al. Middle cerebral artery Doppler for the prediction of fetal anaemia in cases without hydrops: a practical approach[J]. Br J Radiol, 2002, 75(897):726-730.
[3]	Daniels G. Variants of RhD--current testing and clinical consequences[J]. Br J Haematol, 2013, 16(14):461-470.
[4]	田兆嵩. 临床输血学[M]. 2版. 北京：人民卫生出版社，2002: 178.
[5]	Bowman JM. Controversies in Rhprophylaxis: who needs Rhimmune globulin and when should it be given？[J]. Am J Obstet Gynecol, 1985, 151(3):289-294.
[6]	Bowman J. Rh-immunoglobulin: Rhprophylaxis[J]. Best Pract Res Clin Haemato, 2006, 19(1):27-34.
[7]	American College Obstetricians, Gynecologists, American Academy of Pediatrics. Guidelines for Perinatal Care[M]. 7th ed. Washington: Amer Academy of Pediatrics, 2012：164-167.
[8]	Tynan JA, Angkachatchai V, EhrichM, et al. Multiplexed analysis of circulating cell-free fetal nucleic acids for noninvasive prenatal diagnostic RHD testing[J]. Am J Obstet Gynecol, 2011, 204(3):251.e1-e6.
[9]	Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses[J]. N Engl J Med, 2000, 342(1):9-14.
[10]	Oepkes D, Seaward PG, Vandenbussche FP, et al. Doppler ultrasonography versus amniocentesis to predict fetal anemia[J]. N Engl J Med, 2006, 355(2):156-164.
[11]	Zipursky A, Paul VK. The global burden of Rh disease[J]．Arch Dis Child Fetal Neonatal Ed, 2011, 96(2):F84-F85.
[12]	Coopamah MD, Freeman J, Semple JW. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist[J]. Blood, 2003, 102(8):2862-2867.
[13]	Boruchov AM, Heller G, Veri MC, et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions[J]. J Clin Invest, 2005, 115(10):2914-2923.
[14]	Kumpel BM. On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis)[J]. Immunology Letters, 2002, 82(1-2):67-73.
[15]	Daniels G. Variants of RhD--current testing and clinical consequences[J]. Br J Haematol, 2013, 161(4):461-470.
[16]	Cunningham FG, Leveno KJ, Bloom SL, et al. Williams obstetrics[M]. 24th ed. New York: McGraw-Hill Education, 2014：312.
[17]	Chambers E, Davies L, Evans S, et al. Comparison of haemoglobin F detection by the acidelution test, flow cytometry and high-performance liquidchromatography in maternal blood samples analysed for fetomaternal haemorrhage[J]. Transfus Med, 2012, 22(3):199-204.
[18]	Chilcott J, Lloyd JM, Wight J, et al. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative[J]. Health Technol Assess, 2003, 7(4):iii-62.
[19]	Kent J, Farrell AM, Soothill P. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice[J]. BMC Pregnancy Childbirth, 2014, 14:87.
[20]	Fox C, Martin W, Somerset DA, et al. Early intraperitoneal transfusion and adjuvant maternal immunoglobulin therapy in the treatment of severe red cell alloimmunization prior to fetal intravascular transfusion[J]. Fetal Diagn Ther, 2008, 23(2):159-163.
[21]	Scheier M, Hernandez-Andrade E, Fonseca EB, et al. Prediction of severe fetal anemia in red blood cell alloimmunization after previous intrauterine transfusion[J]. Am J Obstet Gynecol, 2006，195 (6):1550-1556.
[22]	van Kamp IL, Klumper FJ, Oepkes D, et al. Complications of intrauterine intravascular transfusion for fetalanemia due to maternalred-cellalloimmunization[J]. Am J Obstet Gynecol, 2005, 192(1):171-177.
[23]	Lindenburg IT, van Kamp IL, van Zwet EW, et al. Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation[J]. BJOG, 2013, 120(7):847-852.
[24]	Lindenburg IT, Smits-Wintjens VE, van Klink JM, et al. Long-term neurodevelopmentaloutcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study[J]. Am J Obstet Gynecol, 2012, 206(2):141.e1-e8.

Please choose a citation manager

Content to export